School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Chrystal Paulos

  • Department of Surgery
    Associate Professor
  • chrystal.mary.paulos@emory.edu
Head shot of Chrystal Paulos

Overview

Prior to joining Emory, Dr. Paulos was the Cecilia and Vincent Peng Endowed Chair in Melanoma at the Medical University of South Carolina. She also served as co-leader of the Cancer Immunology Research Program and director of the Adoptive Cancer Immunotherapy Program at Hollings Cancer Center in Charleston, SC.

Dr. Paulos received her PhD in Biochemistry from Purdue University in West Lafayette, IN. She completed her post-doctoral training in genetherapy at the University of Pennsylvania in Philadelphia, and in tumor immunology at the National Institutes of Health in Bethesda, MD.

The objective of Dr. Paulos' research is to develop novel T cell-based therapies for patients with melanoma. Her laboratory seeks to identify mechanisms underlying protective immunity in solid tumors, with an emphasis on adoptive T cell transfer (ACT) therapy. By combining basic and translational understanding of human T cells in clinical studies with mechanistic studies in relevant mouse models and in investigator-initiated clinical trials in patients, her research team has contributed significant insight into the various roles of how to mount T cell memory responses to tumors.

Academic Appointment

  • David H. Lawson Professorship in Cancer Research, Emory University School of Medicine
  • Acting Associate Professor, Department of Microbiology and Immunology, Emory University School of Medicine

Education

Degrees

  • BS with Honors from Truman State University, Kirksville, MO, Class of 1997
  • PhD in Biochemistry from Purdue University, West Lafayette, IN, 1998-2004

Research

Focus

  • To develop novel T cell-based therapies for patients with melanoma.

    Dr. Paulo's laboratory seeks to identify mechanisms underlying protective immunity in solid tumors with an emphasis on adoptive T cell transfer (ACT) therapy.

Publications

  • XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial.
    Oncoimmunology Volume: 14 Page(s): 2475620
    12/01/2025 Authors: Phillips MJ; Alese OB; Horvat NK; Greene E; Gbolahan OB; Coleman K; Doxie DB; Parihar V; Mahdi ZK; McCook-Veal A
  • MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer.
    Nat Commun Volume: 16 Page(s): 3552
    04/15/2025 Authors: Chi JJ; Xie P; Cheng MH; Zhu Y; Cui X; Watson J; Zeng L; Uddin A; Nguyen H; Li L
  • Combination radiation and PD-L1 enhance tumor control by stimulating CD8+PD-1+TCF-1+T cells in the tumor-draining lymph node.
    Nat Commun Volume: 16 Page(s): 3522
    04/14/2025 Authors: Shen Y; Connolly E; Aiello M; Zhou C; Chappa P; Song H; Tippitak P; Clark T; Cardenas M; Prokhnevska N
  • Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcRIIB+CD8+ T cells in melanoma.
    JCI Insight Volume: 10
    03/24/2025 Authors: Bennion KB; Miranda R Bazzano J; Liu D; Wagener M; Paulos CM; Ford ML
  • CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors.
    J Immunother Cancer Volume: 13
    02/11/2025 Authors: Mohamed AO; Boone DT; Ferry SL; Peck MC; Santos AM; Soderholm HE; Wittling MC; Paulos C; Turk MJ; Huang YH
  • A Paradigm Shift in Tumor Immunology: Th17 Cells and TGF in Intestinal Cancer Initiation.
    Cancer Res Volume: 84 Page(s): 3919 - 3920
    12/02/2024 Authors: Wyatt MM; Paulos CM
  • Editor's Note: Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor.
    Cancer Res Volume: 84 Page(s): 3702
    11/04/2024 Authors: Zhao Y; Moon E; Carpenito C; Paulos CM; Liu X; Brennan AL; Chew A; Carroll RG; Scholler J; Levine BL
  • Strategies for Improving CAR T Cell Persistence in Solid Tumors.
    Cancers (Basel) Volume: 16
    08/16/2024 Authors: Wittling MC; Cole AC; Brammer B; Diatikar KG; Schmitt NC; Paulos CM
  • Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.
    J Immunother Cancer Volume: 12
    06/30/2024 Authors: Wittling MC; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Cole AC; Lesinski GB; Paulos CM
  • CD8+ T cell-derived Fgl2 regulates immunity in a cell-autonomous manner via ligation of FcRIIB.
    Nat Commun Volume: 15 Page(s): 5280
    06/20/2024 Authors: Bennion KB; Liu D; Dawood AS; Wyatt MM; Alexander KL; Abdel-Hakeem MS; Paulos CM; Ford ML
  • IL15 and IL21: Better When Membrane-Tethered Together on Antitumor T Cells.
    Clin Cancer Res Volume: 30 Page(s): 1431 - 1433
    04/15/2024 Authors: Ruffin AT; Wittling MC; Cole AC; Paulos CM
  • Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node.
    Res Sq
    03/06/2024 Authors: Shen Y; Connolly E; Aiello M; Zhou C; Chappa P; Song H; Tippitak P; Clark T; Cardenas M; Prokhnevska N
  • Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
    J Immunother Cancer Volume: 12
    01/08/2024 Authors: Horvat NK; Karpovsky I; Phillips M; Wyatt MM; Hall MA; Herting CJ; Hammons J; Mahdi Z; Moffitt RA; Paulos CM
  • Progressively Enhancing Stemness of Adoptively Transferred T Cells with PI3K Blockade Improves Metabolism and Antitumor Immunity.
    Cancer Res Volume: 84 Page(s): 69 - 83
    01/02/2024 Authors: Rangel Rivera GO; Dwyer CJ; Knochelmann HM; Smith AS; Aksoy BA; Cole AC; Wyatt MM; Kumaresan S; Thaxton JE; Lesinski GB
  • Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.
    bioRxiv
    12/18/2023 Authors: Wittling MC; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Cole AC; Lesinski GB; Paulos CM
  • FcRIIB expressed on CD8+ T cells limits responsiveness to PD-1 checkpoint inhibition in cancer.
    Sci Transl Med Volume: 15 Page(s): eadd1868
    08/23/2023 Authors: Bennion KB; Tariq M; Wyatt MM; Duneton C; Baecher KM; Paulos CM; Kudchadkar RR; Lowe MC; Ford ML
  • Does non-metastatic gastric cancer of the cardia warrant a different treatment strategy?
    J Surg Oncol Volume: 128 Page(s): 231 - 241
    08/01/2023 Authors: Ajay PS; NeMoyer R; Goyal S; Switchenko JM; Lin Y; Jabbour SK; Carpizo DR; Paulos CM; Kennedy TJ; Shah MM
  • Impact of nodal status in determining multimodal treatment strategies in non-cardia gastric cancer.
    J Surg Oncol Volume: 128 Page(s): 242 - 253
    08/01/2023 Authors: Ajay PS; Sok CP; Goyal S; Switchenko JM; Maegawa FB; Gillespie TW; Paulos CM; Lesinski GB; Kooby DA; Kennedy TJ
  • Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
    J Transl Med Volume: 21 Page(s): 488
    07/20/2023 Authors: Ascierto PA; Avallone A; Bifulco C; Bracarda S; Brody JD; Emens LA; Ferris RL; Formenti SC; Hamid O; Johnson DB
  • Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells.
    Mol Ther Volume: 31 Page(s): 2120 - 2131
    07/05/2023 Authors: Wyatt MM; Huff LW; Nelson MH; Neal LR; Medvec AR; Rangel Rivera GO; Smith AS; Rivera Reyes AM; Knochelmann HM; Riley JL
  • Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients.
    J Transl Med Volume: 21 Page(s): 318
    05/11/2023 Authors: Galati D; Zanotta S; Capone M; Madonna G; Mallardo D; Romanelli M; Simeone E; Festino L; Sparano F; Azzaro R
  • Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner.
    JCI Insight Volume: 8
    04/24/2023 Authors: Ware MB; Phillips M; McQuinn C; Zaidi MY; Knochelmann HM; Greene E; Robinson B; Herting CJ; Mace TA; Chen Z
  • Adhesion analysis via a tumor vasculature-like microfluidic device identifies CD8+ Tcells with enhanced tumor homing to improve cell therapy.
    Cell Rep Volume: 42 Page(s): 112175
    03/28/2023 Authors: Camargo CP; Muhuri AK; Alapan Y; Sestito LF; Khosla M; Manspeaker MP; Smith AS; Paulos CM; Thomas SN
  • The degree of T cell stemness differentially impacts the potency of adoptive cancer immunotherapy in a Lef-1 and Tcf-1 dependent manner.
    bioRxiv
    03/10/2023 Authors: Rangel Rivera GO; Dwyer CJ; Knochelmann HM; Smith AS; Aksoy A; Cole AC; Wyatt MM; Thaxton JE; Lesinski GB; Paulos CM
  • Time to First Treatment and Optimal Adjuvant Treatment Strategy in Resectable Gastric Cancer Patients Pathologically Upstaged to Lymph Node Positive Disease
    Volume: 30 Page(s): S161 - S161
    03/01/2023 Authors: Ajay PS; Sok CP; Goyal S; Switchenko J; Maegawa F; Gillespie TW; Paulos C; Kooby DA; Kennedy T; Shah MM
  • Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models.
    J Immunother Cancer Volume: 11
    01/01/2023 Authors: Kansal V; Burnham AJ; Kinney BLC; Saba NF; Paulos C; Lesinski GB; Buchwald ZS; Schmitt NC
  • The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy.
    Front Immunol Volume: 14 Page(s): 1154566
    01/01/2023 Authors: Zhang H; Passang T; Ravindranathan S; Bommireddy R; Jajja MR; Yang L; Selvaraj P; Paulos CM; Waller EK
  • Stress-Mediated Attenuation of Translation Undermines T-cell Activity in Cancer.
    Cancer Res Volume: 82 Page(s): 4386 - 4399
    12/02/2022 Authors: Riesenberg BP; Hunt EG; Tennant MD; Hurst KE; Andrews AM; Leddy LR; Neskey DM; Hill EG; Rivera GOR; Paulos CM
  • PROTEASOME MEDIATED PROTEIN CATABOLISM FUELS ANTITUMOR IMMUNITY
    Volume: 10 Page(s): A1086 - A1086
    11/01/2022 Authors: Riesenberg B; Hunt E; Tennant M; Hurst K; Andrews A; Leddy L; Neskey D; Hill E; Rivera GR; Paulos C
  • MULTIPLEXED ION BEAM IMAGING (MIBI) UNCOVERS ADAPTIVE IMMUNE RESPONSES ASSOCIATED WITH CLINICAL OUTCOMES IN ORAL CAVITY SQUAMOUS CELL CARCINOMA TREATED WITH NEOADJUVANT PD-1 INHIBITOR
    Volume: 10 Page(s): A97 - A97
    11/01/2022 Authors: Padmanabhan R; Knochelmann H; Hav M; Nagy M; Si P; Bajaj S; Lesinski G; Neskey D; Paulos C
  • THE ROLE OF CD26 IN PANCREATIC DUCTAL ADENOCARCINOMA
    Volume: 10 Page(s): A1516 - A1516
    11/01/2022 Authors: Ware B; Hammons J; Karpovsky I; Wyatt M; Mace T; Maithel S; El-Rayes B; Paulos C; Lesinski G; Phillips M
  • FC gamma RIIB EXPRESSED ON CD8 T CELLS LIMITS RESPONSIVENESS TO PD-1 CHECKPOINT INHIBITION IN CANCER
    Volume: 10 Page(s): A529 - A529
    11/01/2022 Authors: Bennion K; Tariq M; Wyatt M; Baecher K; Paulos C; Kudchadkar R; Lowe M; Ford M
  • Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer.
    Clin Cancer Res Volume: 28 Page(s): 4336 - 4345
    10/03/2022 Authors: Ruggieri AN; Yarchoan M; Goyal S; Liu Y; Sharon E; Chen HX; Olson BM; Paulos CM; El-Rayes BF; Maithel SK
  • Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis.
    World J Otorhinolaryngol Head Neck Surg Volume: 8 Page(s): 177 - 186
    09/01/2022 Authors: Levy DA; Patel JJ; Nguyen SA; Nicholas Jungbauer W; Neskey DM; Cohen EEW; Paulos CM; Kaczmar JA; Knochelmann HM; Day TA
  • Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors.
    J Geriatr Oncol Volume: 13 Page(s): 1003 - 1010
    09/01/2022 Authors: Howell AV; Gebregziabher M; Thiers BH; Graboyes EM; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
  • Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE.
    Lupus Sci Med Volume: 9
    07/01/2022 Authors: Kamen DL; Wallace C; Li Z; Wyatt M; Paulos C; Wei C; Wang H; Wolf BJ; Nietert PJ; Gilkeson G
  • Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021.
    J Transl Med Volume: 20 Page(s): 257
    06/07/2022 Authors: Ascierto PA; Avallone A; Bhardwaj N; Bifulco C; Bracarda S; Brody JD; Buonaguro L; Demaria S; Emens LA; Ferris RL
  • B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity.
    J Immunother Cancer Volume: 10
    01/01/2022 Authors: Smith AS; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Rivera-Reyes AM; Dwyer CJ; Ware MB; Cole AC; Neskey DM; Rubinstein MP
  • Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition.
    Front Oncol Volume: 12 Page(s): 836845
    01/01/2022 Authors: Knochelmann HM; Ware MB; Rali A; Linderman S; Shantha JG; Lawson DH; Yushak M; Swerlick R; Paulos CM; Yeh S
  • Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
    Lancet Oncol Volume: 22 Page(s): 1777 - 1786
    12/01/2021 Authors: Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM
  • TLR9-ACTIVATED B CELLS DIRECTLY LICENSE ADOPTIVELY TRANSFERRED CD8+T CELLS WITH POTENT TUMOR IMMUNITY
    Volume: 9 Page(s): A207 - A207
    11/01/2021 Authors: Smith A; Knochelmann H; Wyatt M; RIvera GR; Ware B; Reyes AR; Dwyer C; Neskey D; Rubinstein M; Liu B
  • POTENT INHIBITION OF PI3K delta PROMOTES ENHANCED T CELL STEMNESS AND MITOCHONDRIAL FITNESS
    Volume: 9 Page(s): A237 - A237
    11/01/2021 Authors: RIvera GR; Dwyer C; Knochelmann H; Smith A; Cole A; Wyatt M; Ware B; Paulos C
  • BRAF MUTATIONS ARE ASSOCIATED WITH T-HELPER CELL INFILTRATION AND POLARIZATION IN MELANOMA
    Volume: 9 Page(s): A9 - A9
    11/01/2021 Authors: Ware M; Pavuluri B; Smith A; Wyatt M; RIvera GR; Cole A; Paulos C
  • NOVEL WAYS TO EXPLOIT IL-21 TO AUGMENT ADOPTIVE T CELL TRANSFER THERAPY AGAINST TUMORS
    Volume: 9 Page(s): A737 - A737
    11/01/2021 Authors: Cole A; RIvera GR; Smith A; Wyatt M; Ware B; Knochelmann H; Paulos C
  • REPURPOSING CD26 (DPP4) INHIBITORS TO ENHANCE IMMUNOTHERAPY RESPONSE IN PANCREATIC DUCTAL ADENOCARCINOMA
    Volume: 9 Page(s): A948 - A949
    11/01/2021 Authors: Phillips M; Ware M; Herting C; Mace T; Maithel S; Sarmiento J; El-Rayes B; Paulos C; Wyatt M; Lesinski G
  • Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.
    Cell Rep Med Volume: 2 Page(s): 100411
    10/19/2021 Authors: Liu S; Knochelmann HM; Lomeli SH; Hong A; Richardson M; Yang Z; Lim RJ; Wang Y; Dumitras C; Krysan K
  • Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
    Cell Rep Med Volume: 2 Page(s): 100426
    10/19/2021 Authors: Knochelmann HM; Horton JD; Liu S; Armeson K; Kaczmar JM; Wyatt MM; Richardson MS; Lomeli SH; Xiong Y; Graboyes EM
  • Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor- (ROR) Agonist for Use in Treating Cancer.
    J Med Chem Volume: 64 Page(s): 13410 - 13428
    09/23/2021 Authors: Aicher TD; Van Huis CA; Hurd AR; Skalitzky DJ; Taylor CB; Beleh OM; Glick G; Toogood PL; Yang B; Zheng T
  • Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy).
    J Transl Med Volume: 19 Page(s): 238
    06/02/2021 Authors: Ascierto PA; Bifulco C; Ciardiello F; Demaria S; Emens LA; Ferris R; Formenti SC; Galon J; Khleif SN; Kirchhoff T
  • Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma.
    J Geriatr Oncol Volume: 12 Page(s): 394 - 401
    04/01/2021 Authors: Howell AV; Gebregziabher M; Thiers BH; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
  • Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities.
    Cancer Med Volume: 10 Page(s): 1805 - 1814
    03/01/2021 Authors: Curran T; Sun Z; Gerry B; Findlay VJ; Wallace K; Li Z; Paulos C; Ford M; Rubinstein MP; Chung D
  • The evolving landscape of immunotherapy in solid tumors.
    J Surg Oncol Volume: 123 Page(s): 798 - 806
    03/01/2021 Authors: Keilson JM; Knochelmann HM; Paulos CM; Kudchadkar RR; Lowe MC
  • Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).
    J Transl Med Volume: 19 Page(s): 13
    01/06/2021 Authors: Ascierto PA; Butterfield LH; Campbell K; Daniele B; Dougan M; Emens LA; Formenti S; Janku F; Khleif SN; Kirchhoff T
  • Effective Activation and Expansion of Canine Lymphocytes Using a Novel Nano-Sized Magnetic Beads Approach.
    Front Immunol Volume: 12 Page(s): 604066
    01/01/2021 Authors: Szopa IM; Granica M; Bujak JK; abd A; Baszczyk M; Paulos CM; Majchrzak-Kuligowska K
  • Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy.
    Front Immunol Volume: 12 Page(s): 645242
    01/01/2021 Authors: Rangel Rivera GO; Knochelmann HM; Dwyer CJ; Smith AS; Wyatt MM; Rivera-Reyes AM; Thaxton JE; Paulos CM
  • Preinvasive Colorectal Lesions of African Americans Display an Immunosuppressive Signature Compared to Caucasian Americans.
    Front Oncol Volume: 11 Page(s): 659036
    01/01/2021 Authors: Wallace K; Nahhas GJ; Bookhout C; Lewin DN; Paulos CM; Nikolaishvili-Feinberg N; Cohen SM; Guglietta S; Bakhtiari A; Camp ER
  • Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies.
    Oncoimmunology Volume: 10 Page(s): 1959101
    01/01/2021 Authors: Knochelmann HM; Rivera-Reyes AM; Wyatt MM; Smith AS; Chamness R; Dwyer CJ; Bobian M; Rangel Rivera GO; Horton JD; Lilly M
  • Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K- and -.
    Front Immunol Volume: 12 Page(s): 718621
    01/01/2021 Authors: Chandrasekaran S; Funk CR; Kleber T; Paulos CM; Shanmugam M; Waller EK
  • TLR9-ACTIVATED B CELLS IMPRINT ADOPTIVELY TRANSFERRED CD8+T CELLS WITH POTENT TUMOR IMMUNITY AND PERSISTENCE IN VIVO
    Volume: 8 Page(s): A96 - A97
    11/01/2020 Authors: Smith A; Knochelmann H; Wyatt M; Dwyer C; Rivera GR; Reyes AR; Thaxton J; Bartee E; Rubinstein M; Liu B
  • IL-6 IS CRITICAL FOR MEMORY RESPONSES ELICITED BY TH17 CELLS TO TUMORS
    Volume: 8 Page(s): A72 - A73
    11/01/2020 Authors: Knochelmann H; Dwyer C; Smith A; Wyatt M; RIvera GR; Lesinski G; Li Z; Rubinstein M; Paulos C
  • ADOPTIVELY TRANSFERRED CD8+T CELLS THAT TARGET NEOANTIGEN PERSIST AND REGRESS MELANOMAS TO A GREATER EXTENT THAN THOSE THAT TARGET SELF/TUMOR-ANTIGEN
    Volume: 8 Page(s): A96 - A96
    11/01/2020 Authors: Reyes AR; Wyatt M; Dwyer C; Knochelmann H; Smith A; Rivera GR; Paulos C
  • CD26 ENZYMATIC ACTIVITY MODULATES EFFICIENT MIGRATION OF ADOPTIVELY TRANSFERRED T CELLS TO SOLID TUMORS
    Volume: 8 Page(s): A315 - A316
    11/01/2020 Authors: Wyatt M; Bailey S; Nelson M; Knochelmann H; Smith A; RIvera GR; Reyes AR; Paulos C
  • INHIBITION OF PI3K delta IMPROVES TUMOR SPECIFIC T CELL IMMUNITY AND METABOLIC FITNESS
    Volume: 8 Page(s): A95 - A96
    11/01/2020 Authors: Rivera GR; RIvera GR; Dwyer C; Arhontoulis D; Knochelmann H; Smith A; Wyatt M; Reyes AR; Paulos C
  • IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors.
    Cancer Res Volume: 80 Page(s): 3920 - 3932
    09/15/2020 Authors: Knochelmann HM; Dwyer CJ; Smith AS; Bowers JS; Wyatt MM; Nelson MH; Rangel Rivera GO; Horton JD; Krieg C; Armeson K
  • Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells.
    Eur J Immunol Volume: 50 Page(s): 1386 - 1399
    09/01/2020 Authors: Dwyer CJ; Arhontoulis DC; Rangel Rivera GO; Knochelmann HM; Smith AS; Wyatt MM; Rubinstein MP; Atkinson C; Thaxton JE; Neskey DM
  • Platelet and hemoglobin count at diagnosis are associated with survival in African American and Caucasian patients with colorectal cancer.
    Cancer Epidemiol Volume: 67 Page(s): 101746
    08/01/2020 Authors: Wallace K; Li H; Brazeal JG; Lewin DN; Sun S; Ba A; Paulos CM; Rachidi S; Li Z; Alekseyenko AV
  • The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019.
    J Immunother Cancer Volume: 8
    08/01/2020 Authors: Ascierto PA; Bifulco C; Galon J; Garbe C; Khleif SN; McQuade J; Odunsi K; Okada H; Paulos CM; Quezada SA
  • Identification of human CD4+ T cell populations with distinct antitumor activity.
    Sci Adv Volume: 6
    07/01/2020 Authors: Nelson MH; Knochelmann HM; Bailey SR; Huff LW; Bowers JS; Majchrzak-Kuligowska K; Wyatt MM; Rubinstein MP; Mehrotra S; Nishimura MI
  • RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity.
    Sci Adv Volume: 6 Page(s): eaaz3865
    05/01/2020 Authors: Ansa-Addo EA; Huang H-C; Riesenberg B; Iamsawat S; Borucki D; Nelson MH; Nam JH; Chung D; Paulos CM; Liu B
  • IL-6 fuels durable memory for Th17 cell-mediated responses to tumors
    Volume: 204
    05/01/2020 Authors: Knochelmann H; Dwyer C; Smith AS; Wyatt M; Rivera GR; Lesinski G; Li Z; Rubinstein M; Paulos CM
  • Inhibition of PI3K delta improves tumor specific T cell immunity and metabolic fitness
    Volume: 204
    05/01/2020 Authors: Rivera GOR; Dwyer C; Arthontoulis D; Knochelmann H; Smith AS; Reyes AR; Wyatt M; Paulos CM
  • CD26 enzymatic activity modulates efficient migration of adoptively transferred cancer-specific T cells to solid tumor
    Volume: 204
    05/01/2020 Authors: Wyatt MM; Bailey S; Knochelmann H; Smith AS; Dwyer C; Rivera GOR; Reyes AR; Nelson M; Paulos CM
  • T cells exhibit prolonged immunity against melanoma tumors expressing high, but not low affinity antigens
    Volume: 204
    05/01/2020 Authors: Reyes AMR; Wyatt MM; Dwyer CJ; Knochelmann HM; Smith AS; Rivera GOR; Paulos CM
  • Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma.
    BMC Cancer Volume: 20 Page(s): 229
    03/17/2020 Authors: Xiong Y; Neskey DM; Horton JD; Paulos CM; Knochelmann HM; Armeson KE; Young MRI
  • IL-6 regulates CTLA4 expression on CD4+T-cells and dual antibody blockade of IL-6 and CTLA4 leads to tumor regression in an orthotopic murine model of pancreatic ductal adenocarcinoma
    Volume: 79
    12/01/2019 Authors: Ware MB; McQuinn C; Mace TA; Bowers J; Shakya R; Farris B; Young G; Carson WE; Paulos CM; El-Rayes B
  • Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).
    J Immunother Cancer Volume: 7 Page(s): 332
    11/29/2019 Authors: Ascierto PA; Bifulco C; Buonaguro L; Emens LA; Ferris RL; Fox BA; Delgoffe GM; Galon J; Gridelli C; Merlano M
  • CD8+T cells break tolerance to tumors in a B cell-dependent manner via TLR9 signaling
    Volume: 7
    11/06/2019 Authors: Smith A; Knochelmann H; Dwyer C; Wyatt M; Rivera GR; Thaxton J; Rubinstein M; Liu B; Bartee E; Paulos C
  • Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity.
    Cell Rep Volume: 28 Page(s): 1879 - 1893.e7
    08/13/2019 Authors: Chakraborty P; Vaena SG; Thyagarajan K; Chatterjee S; Al-Khami A; Selvam SP; Nguyen H; Kang I; Wyatt MW; Baliga U
  • Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy.
    Oncol Rev Volume: 13 Page(s): 430
    07/22/2019 Authors: Bowers JS; Bailey SR; Rubinstein MP; Paulos CM; Camp ER
  • Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.
    Trends Cancer Volume: 5 Page(s): 208 - 232
    04/01/2019 Authors: Horton JD; Knochelmann HM; Day TA; Paulos CM; Neskey DM
  • Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines.
    Front Immunol Volume: 10 Page(s): 263
    01/01/2019 Authors: Dwyer CJ; Knochelmann HM; Smith AS; Wyatt MM; Rangel Rivera GO; Arhontoulis DC; Bartee E; Li Z; Rubinstein MP; Paulos CM
  • Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.
    Pigment Cell Melanoma Res Volume: 32 Page(s): 68 - 78
    01/01/2019 Authors: Eby JM; Smith AR; Riley TP; Cosgrove C; Ankney CM; Henning SW; Paulos CM; Garrett-Mayer E; Luiten RM; Nishimura MI
  • In Vitro Priming of Adoptively Transferred T Cells with a ROR Agonist Confers Durable Memory and Stemness In Vivo.
    Cancer Res Volume: 78 Page(s): 3888 - 3898
    07/15/2018 Authors: Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
  • Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).
    J Immunother Cancer Volume: 6 Page(s): 69
    07/11/2018 Authors: Ascierto PA; Brugarolas J; Buonaguro L; Butterfield LH; Carbone D; Daniele B; Ferris R; Fox BA; Galon J; Gridelli C
  • Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells.
    Cancer Res Volume: 78 Page(s): 3067 - 3074
    06/01/2018 Authors: Johnson CB; May BR; Riesenberg BP; Suriano S; Mehrotra S; Garrett-Mayer E; Salem ML; Jeng EK; Wong HC; Paulos CM
  • When worlds collide: Th17 and Treg cells in cancer and autoimmunity.
    Cell Mol Immunol Volume: 15 Page(s): 458 - 469
    05/01/2018 Authors: Knochelmann HM; Dwyer CJ; Bailey SR; Amaya SM; Elston DM; Mazza-McCrann JM; Paulos CM
  • The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.
    Cancer Volume: 124 Page(s): 1650 - 1659
    04/15/2018 Authors: Riley JM; Cross AW; Paulos CM; Rubinstein MP; Wrangle J; Camp ER
  • N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.
    Cancer Immunol Immunother Volume: 67 Page(s): 691 - 702
    04/01/2018 Authors: Scheffel MJ; Scurti G; Wyatt MM; Garrett-Mayer E; Paulos CM; Nishimura MI; Voelkel-Johnson C
  • Recipient Emphysema Differentially Affects Immunologic Responses During Acute Lung Allograft Rejection in a Pre-Clinical Model
    Volume: 37 Page(s): S210 - S210
    04/01/2018 Authors: Patel KJ; Cheng Q; Allen DP; Aliweah A; Knochelmann H; Paulos C; Goddard M; Nadig SN; Atkinson C
  • Phase 2 Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-surgical Therapy for Locally Advanced Oral Cavity Cancer
    Volume: 100 Page(s): 1315 - 1315
    04/01/2018 Authors: Kaczmar J; Kompelli A; Graboyes E; Hornig J; Lentsch E; Day T; Paulos C; Young MR; Neskey D
  • IL-2 and Beyond in Cancer Immunotherapy.
    J Interferon Cytokine Res Volume: 38 Page(s): 45 - 68
    02/01/2018 Authors: Wrangle JM; Patterson A; Johnson CB; Neitzke DJ; Mehrotra S; Denlinger CE; Paulos CM; Li Z; Cole DJ; Rubinstein MP
  • CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
    Cell Metab Volume: 27 Page(s): 85 - 100.e8
    01/09/2018 Authors: Chatterjee S; Daenthanasanmak A; Chakraborty P; Wyatt MW; Dhar P; Selvam SP; Fu J; Zhang J; Nguyen H; Kang I
  • CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
    Front Immunol Volume: 9 Page(s): 1740
    01/01/2018 Authors: Knochelmann HM; Smith AS; Dwyer CJ; Wyatt MM; Mehrotra S; Paulos CM
  • Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.
    Nat Commun Volume: 8 Page(s): 1961
    12/06/2017 Authors: Bailey SR; Nelson MH; Majchrzak K; Bowers JS; Wyatt MM; Smith AS; Neal LR; Shirai K; Carpenito C; June CH
  • Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis.
    Sci Rep Volume: 7 Page(s): 15552
    11/14/2017 Authors: Scheffel MJ; Helke K; Lu P; Bowers JS; Ogretmen B; Garrett-Mayer E; Paulos CM; Voelkel-Johnson C
  • Combined IL-6 and CTLA4 blockade enhances CD8+T cell infiltration via CXCR3 and limits growth of pancreatic cancer in murine models
    Volume: 5
    11/07/2017 Authors: McQuinn C; Farren M; Mace T; Bowers J; Shakya R; Ferris AB; Young G; Carson W; Paulos C; El-Rayes B
  • CD38-NAD(+) axis regulates immunotherapeutic anti-tumor T cell response
    Volume: 5
    11/07/2017 Authors: Chatterjee S; Daenthanasanmak A; Chakraborty P; Wyatt M; Paulos C; Yu X-Z; Mehrotra S
  • Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer.
    Mol Ther Volume: 25 Page(s): 1995 - 1996
    09/06/2017 Authors: Wrangle J; Paulos CM; Smith TW; Nishimura MI; Rubinstein MP
  • Modulation of Endoplasmic Reticulum Stress Controls CD4+ T-cell Activation and Antitumor Function.
    Cancer Immunol Res Volume: 5 Page(s): 666 - 675
    08/01/2017 Authors: Thaxton JE; Wallace C; Riesenberg B; Zhang Y; Paulos CM; Beeson CC; Liu B; Li Z
  • Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis.
    Cancer Immunol Immunother Volume: 66 Page(s): 737 - 751
    06/01/2017 Authors: Neitzke DJ; Bowers JS; Andrijauskaite K; O'Connell NS; Garrett-Mayer E; Wrangle J; Li Z; Paulos CM; Cole DJ; Rubinstein MP
  • Platelets subvert T cell immunity against cancer via GARP-TGF axis.
    Sci Immunol Volume: 2
    05/05/2017 Authors: Rachidi S; Metelli A; Riesenberg B; Wu BX; Nelson MH; Wallace C; Paulos CM; Rubinstein MP; Garrett-Mayer E; Hennig M
  • Understanding how immune checkpoint modulators alter pre-existing rheumatologic disorders in cancer patients
    Volume: 198
    05/01/2017 Authors: Nelson M; Shirai K; Gupta R; Gilkeson G; Paulos CM
  • -catenin and PI3K inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.
    JCI Insight Volume: 2
    04/20/2017 Authors: Majchrzak K; Nelson MH; Bowers JS; Bailey SR; Wyatt MM; Wrangle JM; Rubinstein MP; Varela JC; Li Z; Himes RA
  • Resident memory T cells in the skin mediate durable immunity to melanoma.
    Sci Immunol Volume: 2
    04/14/2017 Authors: Malik BT; Byrne KT; Vella JL; Zhang P; Shabaneh TB; Steinberg SM; Molodtsov AK; Bowers JS; Angeles CV; Paulos CM
  • Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
    J Hematol Oncol Volume: 10 Page(s): 82
    04/07/2017 Authors: Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB
  • Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.
    Transplantation Volume: 101 Page(s): e75 - e85
    04/01/2017 Authors: Zhu P; Bailey SR; Lei B; Paulos CM; Atkinson C; Tomlinson S
  • Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion.
    JCI Insight Volume: 2 Page(s): e90772
    03/09/2017 Authors: Bowers JS; Nelson MH; Majchrzak K; Bailey SR; Rohrer B; Kaiser AD; Atkinson C; Gattinoni L; Paulos CM
  • PI3K Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells.
    Front Immunol Volume: 8 Page(s): 1221
    01/01/2017 Authors: Bowers JS; Majchrzak K; Nelson MH; Aksoy BA; Wyatt MM; Smith AS; Bailey SR; Neal LR; Hammerbacher JE; Paulos CM
  • The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.
    J Immunol Res Ther Volume: 2 Page(s): 68 - 79
    01/01/2017 Authors: Neal LR; Bailey SR; Wyatt MM; Bowers JS; Majchrzak K; Nelson MH; Haupt C; Paulos CM; Varela JC
  • Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.
    Cancer Res Volume: 76 Page(s): 5229 - 5240
    09/15/2016 Authors: Banerjee A; Thyagarajan K; Chatterjee S; Chakraborty P; Kesarwani P; Soloshchenko M; Al-Hommrani M; Andrijauskaite K; Moxley K; Janakiraman H
  • Optimization of Folate-Targeted Immunotherapy for the Treatment of Experimental Arthritis.
    Inflammation Volume: 39 Page(s): 1345 - 1353
    08/01/2016 Authors: Varghese B; Paulos C; Low PS
  • CD4(+)CD26(+) T cells exhibit enhanced persistence and antitumor activity in vivo
    Volume: 46 Page(s): 130 - 130
    08/01/2016 Authors: Bailey S; Nelson M; Butcher A; Majchrzak K; Bowers J; Meek M; Neal L; Paulos C
  • ROR gamma agonists regulate immune checkpoint receptors to enhance anti-tumor immunity
    Volume: 76
    07/01/2016 Authors: Hu X; Liu X; Moisan J; Paulos C; Wang Y; Spooner C; Lesch C; Morgan R; Mertz D; Bousley D
  • A feasibility and safety study of vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with advanced pancreatic adenocarcinoma.
    Volume: 34
    05/20/2016 Authors: Mehrotra S; Britten CD; Chin SH; Salem ML; Cloud C; Nelson MH; Paulos C; Garrett-Mayer E; Rubinstein MP; Li Z
  • Harnessing the IL-7/IL-7R axis to improve tumor immunotherapy.
    Oncoimmunology Volume: 5 Page(s): e1122865
    05/01/2016 Authors: Johnson CB; Wrangle J; Mehrotra S; Li Z; Paulos CM; Cole DJ; Surh CD; Rubinstein MP
  • Low signal strength enhances the antitumor activity of human CAR Th17 cells
    Volume: 196
    05/01/2016 Authors: Neal LR; Huff LW; Nelson M; Meek ME; Bailey SR; Bowers JS; Kundimi S; Mehrotra S; Varela JC; Paulos CM
  • N-acetylcysteine protects melanoma specific cytotoxic T cells from TCR restimulation induced DNA damage and enhances tumor control in vitro and in vivo
    Volume: 196
    05/01/2016 Authors: Scheffel MJ; Scurti G; Simms P; Nelson M; Garrett-Mayer E; Mehrotra S; Paulos CM; Nishimura MI; Voelkel-Johnson C
  • Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.
    Cancer Immunol Immunother Volume: 65 Page(s): 247 - 259
    03/01/2016 Authors: Majchrzak K; Nelson MH; Bailey SR; Bowers JS; Yu X-Z; Rubinstein MP; Himes RA; Paulos CM
  • Synthetic ROR agonists regulate multiple pathways to enhance antitumor immunity.
    Oncoimmunology Volume: 5 Page(s): e1254854
    01/01/2016 Authors: Hu X; Liu X; Moisan J; Wang Y; Lesch CA; Spooner C; Morgan RW; Zawidzka EM; Mertz D; Bousley D
  • Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.
    J Immunother Cancer Volume: 4 Page(s): 6
    01/01/2016 Authors: Nelson MH; Bowers JS; Bailey SR; Diven MA; Fugle CW; Kaiser ADM; Wrzesinski C; Liu B; Restifo NP; Paulos CM
  • IL-2R mediates temporal regulation of IL-2 signaling and enhances immunotherapy.
    Sci Transl Med Volume: 7 Page(s): 311ra170
    10/28/2015 Authors: Su EW; Moore CJ; Suriano S; Johnson CB; Songalia N; Patterson A; Neitzke DJ; Andrijauskaite K; Garrett-Mayer E; Mehrotra S
  • IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells.
    Cancer Gene Ther Volume: 22 Page(s): 360 - 367
    07/01/2015 Authors: Andrijauskaite K; Suriano S; Cloud CA; Li M; Kesarwani P; Stefanik LS; Moxley KM; Salem ML; Garrett-Mayer E; Paulos CM
  • Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
    Clin Cancer Res Volume: 21 Page(s): 2546 - 2557
    06/01/2015 Authors: Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
  • Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.
    Cancer Immunol Immunother Volume: 64 Page(s): 539 - 549
    05/01/2015 Authors: Rubinstein MP; Su EW; Suriano S; Cloud CA; Andrijauskaite K; Kesarwani P; Schwartz KM; Williams KM; Johnson CB; Li M
  • Increasing Th1 phenotype in Th17 cells improves anti-tumor T cells function
    Volume: 194
    05/01/2015 Authors: Chatterjee S; Kesarwani P; Soloshchenko M; Fu J; Paulos C; Yu X-Z; Mehrotra S
  • Novel RORgamma agonists enhance anti-tumor activity of adoptive T cell therapy
    Volume: 194
    05/01/2015 Authors: Carter L; Moisan J; Majchrzak K; Hu X; Morgan R; Liu X; Demock K; Wang Y; Lesch C; Sanchez B
  • The quantity of CD26 on helper T cells correlates with the efficacy of adoptive cancer immunotherapy
    Volume: 194
    05/01/2015 Authors: Bailey S; Nelson M; Bowers J; Majchrzak K; Stefanik L; Paulos C
  • Vitiligo T cell receptor SILv44 imparts a Tc17 profile and anti-tumor reactivity on host T cells
    Volume: 135 Page(s): S8 - S8
    05/01/2015 Authors: Eby J; Klarquist J; Li M; Wainwright D; Watkins S; Westerhof W; Paulos C; Mehrotra S; Garrett-Mayer E; Luiten R
  • Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.
    Cancer Immunol Res Volume: 3 Page(s): 356 - 367
    04/01/2015 Authors: Frigault MJ; Lee J; Basil MC; Carpenito C; Motohashi S; Scholler J; Kawalekar OU; Guedan S; McGettigan SE; Posey AD
  • The inducible costimulator augments Tc17 cell responses to self and tumor tissue.
    J Immunol Volume: 194 Page(s): 1737 - 1747
    02/15/2015 Authors: Nelson MH; Kundimi S; Bowers JS; Rogers CE; Huff LW; Schwartz KM; Thyagarajan K; Little EC; Mehrotra S; Cole DJ
  • Harnessing the Microbiome to Enhance Cancer Immunotherapy.
    J Immunol Res Volume: 2015 Page(s): 368736
    01/01/2015 Authors: Nelson MH; Diven MA; Huff LW; Paulos CM
  • Novel immunotherapies for hematologic malignancies.
    Immunol Rev Volume: 263 Page(s): 90 - 105
    01/01/2015 Authors: Nelson MH; Paulos CM
  • Reducing CD73 expression by IL1-Programmed Th17 cells improves immunotherapeutic control of tumors.
    Cancer Res Volume: 74 Page(s): 6048 - 6059
    11/01/2014 Authors: Chatterjee S; Thyagarajan K; Kesarwani P; Song JH; Soloshchenko M; Fu J; Bailey SR; Vasu C; Kraft AS; Paulos CM
  • Folate receptor- in activated macrophages: ligand binding and receptor recycling kinetics.
    Mol Pharm Volume: 11 Page(s): 3609 - 3616
    10/06/2014 Authors: Varghese B; Vlashi E; Xia W; Ayala Lopez W; Paulos CM; Reddy J; Xu L-C; Low PS
  • Multifunctional CD26hi Th17 cells eradicate large human tumors
    Volume: 192
    05/01/2014 Authors: Nelson M; Bailey S; Huff L; Kundimi S; Paulos C
  • Defining the role of the novel CD4+CD26high T cell subset in adoptive cancer immunotherapy
    Volume: 192
    05/01/2014 Authors: Bailey S; Nelson M; Schwartz K; Bowers J; Paulos C
  • Reduced ectonucleotidase expression on TGF-beta independent Th17 improves tumor control
    Volume: 192
    05/01/2014 Authors: Chatterjee S; Kesarwani P; Thyagarajan K; Soloshchenko M; Webster C; Paulos C; Mehrotra S
  • Th17 cells in cancer: the ultimate identity crisis.
    Front Immunol Volume: 5 Page(s): 276
    01/01/2014 Authors: Bailey SR; Nelson MH; Himes RA; Li Z; Mehrotra S; Paulos CM
  • Human CD26hi Th17 cells eradicate large established mesothelioma
    Volume: 190
    05/01/2013 Authors: Paulos C; Nelson M; Huff L; Kundimi S; Goodyear M
  • Cytokines in the IL-12 Family Distinctly Impact the Functional Fate and Anti-Tumor Activity of TC17 Cells
    Volume: 35 Page(s): 725 - 725
    11/01/2012 Authors: Kundimi S; Nelson MH; Huff LW; Rogers CE; Paulos CM
  • Inducible Costimulator (ICOS) Augments the Antitumor Activity of TC17 Cells
    Volume: 35 Page(s): 726 - 727
    11/01/2012 Authors: Nelson M; Kundimi S; Rogers C; Huff L; Cole D; Rubinstein M; Paulos C
  • Defining the role of ICOS and CD28 costimulation in T(H)17 cell activation, differentiation and tumor immunity
    Volume: 188
    05/01/2012 Authors: Nelson M; Huff L; Rogers C; Kundimi S; Paulos C
  • Defining the role of ICOS and CD28 costimulation in T(H)17 cell activation, differentiation and tumor immunity
    Volume: 188
    05/01/2012 Authors: Nelson M; Huff L; Rogers C; Kundimi S; Paulos C
  • Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
    J Am Coll Surg Volume: 214 Page(s): 700 - 707
    04/01/2012 Authors: Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
  • A human memory T cell subset with stem cell-like properties.
    Nat Med Volume: 17 Page(s): 1290 - 1297
    09/18/2011 Authors: Gattinoni L; Lugli E; Ji Y; Pos Z; Paulos CM; Quigley MF; Almeida JR; Gostick E; Yu Z; Carpenito C
  • Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS.
    Blood Volume: 118 Page(s): 3062 - 3071
    09/15/2011 Authors: Zhang Q; Wang H; Kantekure K; Paterson JC; Liu X; Schaffer A; Paulos C; Milone MC; Odum N; Turner S
  • Oncogenic kinase NPM/ALK induces expression of the cell-growth stimulatory receptor ICOS
    Volume: 25
    04/01/2011 Authors: Zhang Q; Wang H; Kantekure K; Paterson JC; Liu X; Schaffer A; Paulos C; Milone MC; Turner S; Odum N
  • Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
    Cancer Res Volume: 70 Page(s): 9053 - 9061
    11/15/2010 Authors: Zhao Y; Moon E; Carpenito C; Paulos CM; Liu X; Brennan AL; Chew A; Carroll RG; Scholler J; Levine BL
  • The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells.
    Sci Transl Med Volume: 2 Page(s): 55ra78
    10/27/2010 Authors: Paulos CM; Carpenito C; Plesa G; Suhoski MM; Varela-Rohena A; Golovina TN; Carroll RG; Riley JL; June CH
  • Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.
    J Clin Invest Volume: 120 Page(s): 76 - 80
    01/01/2010 Authors: Paulos CM; June CH
  • Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
    J Immunother Volume: 33 Page(s): 1 - 7
    01/01/2010 Authors: Wrzesinski C; Paulos CM; Kaiser A; Muranski P; Palmer DC; Gattinoni L; Yu Z; Rosenberg SA; Restifo NP
  • Type 17 CD8+ T cells display enhanced antitumor immunity.
    Blood Volume: 114 Page(s): 596 - 599
    07/16/2009 Authors: Hinrichs CS; Kaiser A; Paulos CM; Cassard L; Sanchez-Perez L; Heemskerk B; Wrzesinski C; Borman ZA; Muranski P; Restifo NP
  • Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.
    Nat Med Volume: 15 Page(s): 808 - 813
    07/01/2009 Authors: Gattinoni L; Zhong X-S; Palmer DC; Ji Y; Hinrichs CS; Yu Z; Wrzesinski C; Boni A; Cassard L; Garvin LM
  • Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
    Blood Volume: 112 Page(s): 4746 - 4754
    12/01/2008 Authors: Boni A; Muranski P; Cassard L; Wrzesinski C; Paulos CM; Palmer DC; Gattinoni L; Hinrichs CS; Chan C-C; Rosenberg SA
  • Tumor-specific Th17-polarized cells eradicate large established melanoma.
    Blood Volume: 112 Page(s): 362 - 373
    07/15/2008 Authors: Muranski P; Boni A; Antony PA; Cassard L; Irvine KR; Kaiser A; Paulos CM; Palmer DC; Touloukian CE; Ptak K
  • Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
    Proc Natl Acad Sci U S A Volume: 105 Page(s): 8061 - 8066
    06/10/2008 Authors: Palmer DC; Chan C-C; Gattinoni L; Wrzesinski C; Paulos CM; Hinrichs CS; Powell DJ; Klebanoff CA; Finkelstein SE; Fariss RN
  • IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
    Blood Volume: 111 Page(s): 5326 - 5333
    06/01/2008 Authors: Hinrichs CS; Spolski R; Paulos CM; Gattinoni L; Kerstann KW; Palmer DC; Klebanoff CA; Rosenberg SA; Leonard WJ; Restifo NP
  • IL12 polarization of mouse and human T-cells: implications for adoptive immunotherapy
    Volume: 22
    04/01/2008 Authors: Johnson LA; Kaiser A; Paulos CM; Powell DJ; Heemskerk B; Restifo NP; Rosenberg SA
  • Adoptive immunotherapy: good habits instilled at youth have long-term benefits.
    Immunol Res Volume: 42 Page(s): 182 - 196
    01/01/2008 Authors: Paulos CM; Suhoski MM; Plesa G; Jiang T; Basu S; Golovina TN; Jiang S; Aqui NA; Powell DJ; Levine BL
  • T-cell receptor gene therapy of established tumors in a murine melanoma model.
    J Immunother Volume: 31 Page(s): 1 - 6
    01/01/2008 Authors: Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC
  • Toll-like receptors in tumor immunotherapy.
    Clin Cancer Res Volume: 13 Page(s): 5280 - 5289
    09/15/2007 Authors: Paulos CM; Kaiser A; Wrzesinski C; Hinrichs CS; Cassard L; Boni A; Muranski P; Sanchez-Perez L; Palmer DC; Yu Z
  • MEDI 227-Folate receptor-targeted therapies for inflammatory and autoimmune diseases
    Volume: 234
    08/19/2007 Authors: Low PS; Paulos CM; Varghese B
  • Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
    J Clin Invest Volume: 117 Page(s): 2197 - 2204
    08/01/2007 Authors: Paulos CM; Wrzesinski C; Kaiser A; Hinrichs CS; Chieppa M; Cassard L; Palmer DC; Boni A; Muranski P; Yu Z
  • Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
    J Clin Invest Volume: 117 Page(s): 492 - 501
    02/01/2007 Authors: Wrzesinski C; Paulos CM; Gattinoni L; Palmer DC; Kaiser A; Yu Z; Rosenberg SA; Restifo NP
  • Treatment of established B16 murine melanoma tumors with Tyrp-1 specific CD4(+) lymphocytes.
    Volume: 108 Page(s): 1054A - 1054A
    11/16/2006 Authors: Muranski P; Boni A; Paulos CM; Irvine KR; Antony PA; Restifo NP
  • Partly MHC matched allogeneic tumor specific T cells mediate tumor regression without inducing GVHD in immunosuppressed host.
    Volume: 108 Page(s): 393B - 393B
    11/16/2006 Authors: Boni A; Muranski P; Wrzesinski C; Kaiser A; Paulos C; Palmer D; Gattinoni L; Restifo NP
  • Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. (vol 176, pg 5255, 2006)
    JOURNAL OF IMMUNOLOGY Volume: 176 Page(s): 7788 - 7788
    06/15/2006 Authors: Antony PA; Paulos CM; Ahmadzadeh M; Akpinarli A; Palmer DC; Sato N; Kaiser A; Heinrichs C; Klebanoff CA; Tagaya Y
  • Interleukin-2-dependent mechanisms of tolerance and immunity in vivo.
    J Immunol Volume: 176 Page(s): 5255 - 5266
    05/01/2006 Authors: Antony PA; Paulos CM; Ahmadzadeh M; Akpinarli A; Palmer DC; Sato N; Kaiser A; Hinrichs CS; Klebanoff CA; Tagaya Y
  • Preferential use of IL-2 by CD25+Foxp3+T regulatory cells during immunity to a tumor/self-antigen
    Volume: 176 Page(s): S219 - S219
    04/01/2006 Authors: Antony PA; Paulos C; Akpinarli A; Palmer D; Restifo N
  • Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis.
    Arthritis Res Ther Volume: 8 Page(s): R77
    01/01/2006 Authors: Paulos CM; Varghese B; Widmer WR; Breur GJ; Vlashi E; Low PS
  • Hematopoietic stem cell transplant with lymphodepletion augments T cell-based adoptive immunotherapy
    Volume: 28 Page(s): 619 - 619
    11/01/2005 Authors: Wrzesinski C; Gattinoni L; Palmer DC; Paulos CM; Yu ZY; Rosenberg SA; Restifo NP
  • IL-2 paradoxically controls tolerance and immunity to a tumor/self-antigen
    Volume: 28 Page(s): 647 - 647
    11/01/2005 Authors: Antony PA; Paulos C; Restifo N
  • Folate-targeted immunotherapy to activated macrophages in rheumatoid arthritis
    Volume: 229 Page(s): U150 - U151
    03/13/2005 Authors: Varghese B; Paulos CM; Breur GJ; Widmer WR; Low PS
  • Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery.
    Mol Pharmacol Volume: 66 Page(s): 1406 - 1414
    12/01/2004 Authors: Paulos CM; Reddy JA; Leamon CP; Turk MJ; Low PS
  • Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis.
    Adv Drug Deliv Rev Volume: 56 Page(s): 1205 - 1217
    04/29/2004 Authors: Paulos CM; Turk MJ; Breur GJ; Low PS
  • Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis.
    Arthritis Rheum Volume: 46 Page(s): 1947 - 1955
    07/01/2002 Authors: Turk MJ; Breur GJ; Widmer WR; Paulos CM; Xu L-C; Grote LA; Low PS
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements